About: Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
Creator	Liu, Jing Ye, Mao Zheng, Jie Chen, Hui-Yong Dai, Hong-Juan Li, Lv Wang, Shu-Ling Xiao, Xiao-Juan Luo, Yu-Hao
source	Medline; PMC
abstract	BACKGROUND: Lycorine, a natural alkaloid extracted from Amaryllidaceae, has shown various pharmacological effects. Recent studies have focused on the potential antitumor activity of lycorine. In our previous study, we found that lycorine decrease the cell viability of leukemia HL-60 cells and multiple myeloma KM3 cells and induces cell apoptosis. However, the effect and molecular mechanism of lycorine on human chronic myelocytic leukemia cells has yet to be determined. METHODS: Human chronic myelocytic leukemia cells K562 were treated with lycorine. Cell viability was monitored using the method of CCK-8. The histone deacetylase (HDAC) enzymatic activity was detected by HDAC colorimetric assay, and the cell cycle was analyzed by flow cytometry. The expression of cell-cycle related proteins were identified using Western blot. RESULTS: In the present study, we further revealed that lycorine can inhibit the proliferation of K562 cells. Analysis of HDAC activity showed that lycroine decreases HDAC enzymatic activities in K562 cells in a dose-dependent manner. Inhibition of HDAC activity has been associated with cell-cycle arrest and growth inhibition. We evaluated the cell cycle distribution after lycorine treatment and found that lycorine causes cell-cycle arrest in the G0/G1 phase. To investigate the mechanism behind this cell cycle arrest, G1-related proteins were assayed by Western blot. After lycorine treatment, cyclin D1 and cyclin-dependent kinase 4 expressions were inhibited and retinoblastoma protein phosphorylation was reduced. Lycorine treatment also significantly upregulated the expression of p53 and its target gene product, p21. CONCLUSIONS: These results suggest that inhibition of HDAC activity is responsible for at least part of the induction of cell-cycle arrest in the G0/G1 phase by lycorine and provide a mechanistic framework for further exploring the use of lycorine as a novel antitumor agent.
has issue date	2012-11-23(xsd:dateTime)
bibo:doi	10.1186/1475-2867-12-49
bibo:pmid	23176676
has license	cc-by
sha1sum (hex)	0e5c57371f4f2cf8e3d56871a391c25ee43aaa4f
schema:url	https://doi.org/10.1186/1475-2867-12-49
resource representing a document's title	Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
has PubMed Central identifier	PMC3537594
has PubMed identifier	23176676
schema:publication	Cancer Cell Int
resource representing a document's body	covid:0e5c57371f4f2cf8e3d56871a391c25ee43aaa4f#body_text
is schema:about of	named entity 'enzymatic activity' named entity 'lycorine' named entity 'colorimetric assay' named entity 'lycorine' named entity 'histone deacetylase' named entity 'cell' named entity 'p21' named entity 'G1 phase' named entity 'Results' named entity 'proliferation' named entity 'Lycorine' named entity 'natural' named entity 'reduced' named entity 'Western blot' named entity 'G1 phase' named entity 'ALKALOID' named entity 'CELL CYCLE' named entity 'TREATED WITH' named entity 'THE CELL' named entity 'K562' named entity 'INHIBITION' named entity 'ENZYMATIC ACTIVITY' named entity 'TARGET GENE' named entity 'STUDY' named entity 'PROLIFERATION' named entity 'REDUCED' named entity 'RESULTS' named entity 'ANTITUMOR' named entity 'HAVE' named entity 'CELL-CYCLE' named entity 'K562 CELLS' named entity 'ACTIVITIES' named entity 'INHIBITION' named entity 'HL-60 CELLS' named entity 'RELATED' named entity 'UPREGULATED' named entity 'MULTIPLE MYELOMA' named entity 'K562 CELLS' named entity 'DETERMINED' named entity 'ARREST' named entity 'ANALYZED' named entity 'BACKGROUND' named entity 'CYCLIN D1' named entity 'TREATMENT' named entity 'IDENTIFIED' named entity 'METHODS' named entity 'EXTRACTED' named entity 'ITS' named entity 'PREVIOUS' named entity 'ARREST' named entity 'CELL-CYCLE' named entity 'PHASE' named entity 'HDAC' named entity 'LYCORINE' named entity 'MOLECULAR MECHANISM' named entity 'PHARMACOLOGICAL' named entity 'HUMAN' named entity 'THESE' named entity 'CELL VIABILITY' named entity 'CAUSES' named entity 'RETINOBLASTOMA PROTEIN' named entity 'GENE PRODUCT' named entity 'LEUKEMIA CELLS' named entity 'AMARYLLIDACEAE' named entity 'PROTEINS' named entity 'PRESENT' named entity 'REVEALED' named entity 'USE OF' named entity 'PART OF' named entity 'LYCORINE' named entity 'OUR' named entity 'EXPRESSION' named entity 'DECREASES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software